Hering-Hanit R
Headache Unit, Department of Neurology, Meir General Hospital, Kfar Sava, and the Sackler Faculty of Medicine, Tel Aviv University, Israel.
Headache. 2000 Jan;40(1):41-4. doi: 10.1046/j.1526-4610.2000.00007.x.
To document the relationship between the 5-HT receptor agonist sumatriptan and a change in the nature of cluster headache in four cases. To relate the findings to the literature on the use of sumatriptan in both cluster headache and migraine.
Studies of the efficacy and adverse effects of long-term treatment with sumatriptan in cluster headache are limited and report conflicting findings.
Four cases are described.
All four patients developed a marked increase in the frequency of attacks 3 to 4 weeks after initiating treatment with the drug for the first time. Three patients also developed a change in headache character, and 2 experienced prolongation of the cluster headache period. Withdrawal of the drug reduced the frequency of headaches and eliminated the newly developed type of headache.
Determination of the effects of long-term use of sumatriptan will result in more precise guidelines for the frequency and duration of treatment with this otherwise extremely beneficial drug.
记录5-羟色胺（5-HT）受体激动剂舒马曲坦与4例丛集性头痛性质改变之间的关系。将研究结果与有关舒马曲坦在丛集性头痛和偏头痛中应用的文献进行关联。
关于舒马曲坦长期治疗丛集性头痛的疗效和不良反应的研究有限，且报告结果相互矛盾。
描述4例病例。
所有4例患者在首次使用该药物治疗3至4周后，发作频率显著增加。3例患者头痛性质也发生改变，2例患者丛集性头痛期延长。停药后头痛频率降低，新出现的头痛类型消失。
确定舒马曲坦长期使用的效果将为这种原本极为有益的药物的治疗频率和持续时间制定更精确的指导原则。
